Editorial 1: ​​Conditional ease

Context

The CDSCO guidelines must not degenerate into a “pay and pass” mechanism that weakens regulatory enforcement.

Introduction

The CDSCO’s new compounding guidelines mark a shift towards decriminalisation and ease of doing business in drug regulation. By allowing settlement of minor violations through fines instead of prosecution, the reform aims to reduce over-criminalisation while improving regulatory efficiency. However, its success depends on preventing misuse and ensuring public accountability.

Context and Objective of the Guidelines

• Background
  • The Central Drugs Standard Control Organization (CDSCO) has issued new guidelines to compound minor drug violations.
  • These guidelines operationalise a legal reform initiated in 2023.
• Earlier Situation
  • Minor or technical non-compliance under the Drugs and Cosmetics Act, 1940 often led to criminal prosecution.
  • This resulted in over-criminalisation and prolonged litigation.
• Core Change: Shift from criminal prosecution to administrative settlement through compounding.

Meaning and Mechanism of Compounding

• What is Compounding
  • Firms can voluntarily report violations and apply to pay a fine.
  • This replaces the need for court proceedings.
• Regulatory Discretion: CDSCO decides whether compounding is allowed before or after prosecution.
• Primary Benefit: Successful compounding grants immunity from prosecution for that specific case.
• Policy Rationale: Supports ease of living and ease of doing business.

Legal Backdrop: Jan Vishwas Amendment

• Legislative Basis
  • Enabled by the Jan Vishwas (Amendment of Provisions) Act.
  • Intended to decriminalise and rationalise offences.
• Expansion of Section 32B
  • More offences under the 1940 Act are now compoundable.
• Examples of Eligible Offences
  • Manufacturing drugs in violation of the Act but not under serious offence categories (Section 27(a–c)).
  • Stocking or exhibiting drugs that are non-spurious and non-adulterated but still non-compliant.

Positive Outcomes of the Reform

• Reduced Criminalisation
  • Especially helpful for record-keeping and disclosure-related violations.
• Improved Regulatory Focus
  • Allows enforcement agencies to concentrate on grave public health risks.
• Administrative Efficiency
  • Saves time, costs, and judicial resources.
• Encouragement of Compliance
  • Promotes self-reporting and corrective behaviour by firms.

Major Risks and Pitfalls

• “Pay and Pass” Concern
  • Compounding may become a routine fine-payment mechanism.
• Broad Definition of Errors
  • Covers a wide range of conduct:
    • Minor documentation lapses
    • Serious compliance failures
• Weak Deterrence
  • If fines are too low, inconsistent, or overused, compliance may decline.
• Repeat Offenders
  • Without transparency, firms may repeatedly benefit from compounding.

Transparency and Accountability Issues

• Lack of Public Disclosure
  • CDSCO is not mandated to publish:
    • Compounding orders
    • Case details (even in redacted form)
• Erosion of Public Trust: Absence of disclosure can reduce confidence in regulatory fairness.
• No External Participation: Consumers and whistle-blowers have no opportunity to make representations.
• Auditability Gap: No public record to verify patterns of repeat violations.

Need for Strong Follow-Up Measures

• Corrective and Preventive Actions: Compounding should be linked to mandatory corrective steps.
• Post-Compounding Oversight: Includes follow-up inspections and compliance verification.
• Public Health Safeguards
  • Where relevant:
    • Product recalls
    • Public alerts
• Long-Term Risk Reduction: Without follow-up, compounding may not reduce systemic risk.

Benefits and Risks of the Compounding Regime

Overall Assessment

• Direction of Reform: The policy is conceptually sound and progressive.
• Condition for Success: Requires transparent reporting, consistent penalties, and robust follow-up.
• Bottom Line: Compounding should act as a compliance-correcting tool, not a substitute for enforcement.

Conclusion

Compounding can be a useful compliance-correcting mechanism if implemented with transparency, deterrent penalties, and strong follow-up actions. Without public disclosure, audits, and corrective oversight, it risks becoming a ‘pay and pass’ regime, undermining public health protection and regulatory credibility.